Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 10/20 | 0.48 |
| ▸ | CA2 | P00918 | 10/20 | 0.48 |
| ▸ | CA9 | Q16790 | 10/20 | 0.48 |
| ▸ | CA12 | O43570 | 8/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110907 | 1.00 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL12892511 | 0.90 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL3313109 | 0.90 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL3313120 | 0.90 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL13614201 | 0.90 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL15031302 | 0.90 | LMNA (0.52) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL3314337 | 0.89 | LMNA (0.55) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL5718815 | 0.89 | LMNA (0.55) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL13352083 | 0.89 | LMNA (0.55) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL13320635 | 0.89 | LMNA (0.55) | LMNATHRBSMN1; SMN2HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537134-B1 | PROCESS FOR PRODUCING A RIBOFURANOSE | HOFFMANN LA ROCHE (CH) | 2006-04-05 | — | — | EP | claimed |
| US-7285660-B2 | for use as viricides; comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a lewis acid and of a solvent | ARCHIMICA S.R.L. (IT) | 2007-10-23 | — | — | US | disclosed |
| US-7034161-B2 | Process for producing a ribofuranose | HOFFMANN-LA ROCHE INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1414836-B1 | PROCESS FOR THE PREPARATION OF L-RIBAVIRIN | CLARIANT LSM ITALIA SPA (IT) | 2004-12-29 | — | — | EP | disclosed |
| US-20040176587-A1 | Process for the preparation of l-ribavirin | ARCHIMICA S.R.L. (IT) | 2004-09-09 | — | — | US | disclosed |
| EP-1414836-A2 | PROCESS FOR THE PREPARATION OF L-RIBAVIRIN | Clariant Life Science Molecules (Italia) SpA (IT) | 2004-05-06 | — | — | EP | disclosed |
| EP-1027359-B9 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | RIBAPHARM INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1027359-B1 | MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF | RIBAPHARM INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6552183-B1 | Moncyclic L-nucleosides analogs | ICN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1302474-A1 | Monocyclic L-nucleosides, analogs and uses thereof | Ribapharm, Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1132393-B1 | L-Ribavirin and uses thereof | ICN PHARMACEUTICALS (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003011883-A2 | PROCESS FOR THE PREPARATION OF L-RIBAVIRIN | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-01-23 | — | — | US | disclosed |
| EP-1254911-A1 | Monocyclic L-nucleosides, analogs and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018186-A1 | Monocyclic L-nucleosides, analogs and uses thereof | PNP, TYMP, SLC29A1 | LMNA 1677/4885THRB 3550/4885SMN1; SMN2 724/4885 |
| US-20040176587-A1 | Process for the preparation of l-ribavirin | RNGTT, CPSF1, GART | LMNA 906/4885THRB 1846/4885SMN1; SMN2 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.